Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4 by Lin, Danyu & Psychiatric GWAS Consortium Bipolar Disorder Working Group



















Bipolar disorder is a severe mood disorder affecting more than 1% of 
the population1. Family, twin and adoption studies consistently have 
found relative risks to first-degree relatives of affected individuals of ~8 
and a concordance of ~40–70% for a monozygotic co-twin of affected 
individuals1,2. Bipolar disorder shares phenotypic similarities with 
other psychiatric diseases, and relatives of individuals with bipolar 
disorder are at an increased risk of schizophrenia, major depression 
and schizoaffective disorder, suggesting a partially shared genetic 
basis for these disorders3,4. Despite robust evidence for heritability, 
causal mutations have not been identified through linkage or candi-
date gene association studies1.
GWAS for bipolar disorder have been performed with multiple 
 partially overlapping samples5–11. In a previous small study, research-
ers reported a genome-wide significant association to DGKH (encod-
ing diacylglycerol kinase eta)5. Subsequently, researchers in another 
study8 identified the region of ANK3 (encoding ankyrin 3) and those 
from a third12 recently reported an association to NCAN (encod-
ing neurocan); other studies did not report genome-wide significant 
loci5,9,10,13. The Psychiatric GWAS Consortium (PGC) was estab-
lished to facilitate the combination of primary genotype data and 
to allow analyses both within and across psychiatric disorders14,15. 
Here, the PGC Bipolar Disorder Working Group reports results from 
our association study of bipolar disorder from 16,731 samples and a 
replication sample of 46,918 individuals.
We received primary genotype and phenotype data (Table 1, 
Supplementary Note and Supplementary Table 1). Results have 
been reported singly6,7,9–11 and in combinations8,9,12 in seven publi-
cations with case and control overlap. We divided the data into 
11 case and control groupings and assigned each individual to only 
one group (Table 1). The final dataset comprised 7,481 unique cases 
and 9,250 unique controls. Cases had the following diagnoses: bipolar 
disorder type 1 (n = 6,289; 84%), bipolar disorder type 2 (n = 824; 
11%) and schizoaffective disorder bipolar (n = 263; 4%), and there 
were 105 individuals with other bipolar diagnoses (1%). We directly 
genotyped 46,234 SNPs in all 11 groups and genotyped 1,016,924 
SNPs in between 2 and 11 groups. Based on reference haplotypes from 
the HapMap phase 2 CEU sample, we imputed missing genotypes 
using BEAGLE16. We analyzed imputed SNP dosages from 2,415,422 
autosomal SNPs with a minor allele frequency ≥1% and imputation 
quality score r2 > 0.3. We performed logistic regression of case status 
on imputed SNP dosage including as covariates five multidimensional 
scaling components (Supplementary Fig. 1) and indicator variables 
for the sample group using PLINK17. The genomic control18 inflation 
factor (λGC) was 1.148. Consistent with previous work suggesting 
a highly polygenic architecture for schizophrenia and bipolar dis-
order19, this estimate likely reflects a mixture of signals arising 
from a large number of true risk variants of weak effect and some 
degree of residual confounding. Nonetheless, we designated an associ-
ation as genome-wide significant only if the genomic-control P value 
(PGC) was below 5 × 10−8 (the nominal P values are labeled ‘Praw’). 
Results for the primary analyses can be found in Supplementary 
Figures 2–4. Supplementary Table 2 lists regions containing SNPs 
with PGC < 5 × 10−5.
Table 2 lists four regions from our primary GWAS analysis that 
contain SNPs with Praw < 5 × 10−8; two regions reached PGC ≤ 5 ×  
10−8 (Supplementary Fig. 4). We detected association in ANK3 
(encoding ankyrin 3) on chromosome 10q21 for the imputed SNP 
rs10994397 (PGC = 7.1 × 10−9, odds ratio (OR) = 1.35). The second 
SNP, rs9371601, was located in SYNE1 (encoding synaptic nuclear 
envelope protein 1) on chromosome 6q25 (PGC = 4.3 × 10−8, OR = 
1.15). The intergenic SNP rs7296288 (PGC = 8.4 × 10−8, OR = 1.15) 
is in a region of linkage disequilibrium (LD) of ~100 kb on chromo-
some 12q13 that contains seven genes. rs12576775 (PGC = 2.1 × 
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10−7, OR = 1.18) is found at chromosome 11q14 in the first intron 
of ODZ4, a human homolog of the Drosophila pair-rule gene ten-m 
(odz). We observed generally consistent signals, with no single study 
driving the overall association results (Supplementary Fig. 5). 
A meta-analysis, under both fixed- and random-effects models, 
yielded similar results (Supplementary Tables 3 and 4).
We sought to replicate these findings in independent samples. We 
selected 38 SNPs with PGC < 5 × 10−5 (Supplementary Table 2). Of 
these, four SNPs were not completely independent signals, and we 
did not use these SNPs for further analyses (Online Methods). We 
received unpublished data from investigators on a further 4,496 cases 
and 42,422 controls for the top 34 independent SNPs (Supplementary 
Table 5). Significantly more SNPs replicated than would be expected 
by chance (Table 3). Four of 34 SNPs had replication P < 0.01, 18 
of 34 SNPs had replication P < 0.05, and 31 of 34 SNPs had a sig-
nal in the same direction of effect (binomial test P = 3.8 × 10−7). 
Within the replication samples, two SNPs remained significant fol-
lowing multiple testing correction. The first SNP, rs4765913, is on 
chromosome 12 in CACNA1C, which encodes the α subunit of the 
L-type voltage-gated calcium channel (replication P = 1.6 × 10−4, 
OR = 1.13). The second SNP, rs10896135, is in a 17-exon 98-kb open 
reading frame of C11orf80 (replication P = 0.0015, OR = 0.91), and 
variants in several other genes are in strong linkage disequilibrium 
with this SNP. We obtained nominally significant replication P val-
ues in another gene encoding a calcium channel subunit, CACNB3 
(replication P = 0.0025, OR = 0.93). Only two of the four SNPs listed 
in Table 2 had replication P < 0.05; the genome-wide significant 
SNPs rs10994397 and rs9371601 did not have P < 0.05 (replication 
P = 0.12 and P = 0.10, respectively). Finally, we performed a fixed-
effects meta-analysis on our effect estimates from the primary and 
replication data and established genome-wide significant evidence for 
association with rs4765913 in CACNA1C (P = 1.52 × 10−8, OR = 1.14) 
and rs12576775 in ODZ4 (P = 4.40 × 10−8, OR = 0.89) (Fig. 1). As in the 
primary analyses, we observed consistent signals, and a meta-analysis 
of the replication data did not reveal significant heterogeneity between 
the samples (Supplementary Tables 6 and 7).
To interpret why two significant associations found in the primary 
analysis fail to replicate, we quantified the effect of the ‘winner’s curse’. 
Given a polygenic model, power will be low to detect a particular 
variant at genome-wide significant levels, but there will be many 
chance opportunities to identify at least one variant. Simulation of 
the distribution of ORs around several ‘true’ ORs, conditioning on 
a genome-wide significant P value of 5 × 10−8, a fixed minor allele 
frequency of 0.20 and our sample size showed a distinct inflation of 
the estimated OR, leading to a marked overestimate of the power to 
replicate an individual result (Supplementary Table 8). For example, 
for a true genotypic relative risk of 1.05, the mean estimated OR is 
1.17 conditioning on P < 5 × 10−8. Although the nominal power for 
replication is 100% for the inflated OR, the true power to replicate at 
P < 0.05 is only 30%. Thus, any single replication failure is by itself 
less informative. This simulation is consistent with our observations 
of higher than expected rate of nominal replications.
We assessed enrichment of Gene Ontology (GO) terms for regions 
containing the top 34 independent SNPs listed in Table 3 (PGC < 
5 × 10−5) using a permutation-based approach that controlled for 
potential biases caused by SNP density, gene density and gene size 
and found enrichment in GO:0015270, the category containing 
voltage gated calcium channel activity. This GO category contains 
eight genes, three of which (CACNA1C, CACNA1D and CACNB3) 
are present among the 34 independent association intervals tested 
(P = 0.00002); the probability of observing an empirical P value this 
small, given all the targets tested, is P = 0.021. Thus, intervals ranked 
highly in our GWAS likely do not represent a random set with respect 
to gene function. Studies based on a larger number of loci, defined 
by more liberal P-value cutoffs, could indicate other promising areas 
for biological investigation.
table 1 Description of individual samples
Sample Ancestry Case (n)a Control (n)b Platformc Referenced
BOMA-Bipolar Study, University of Bonn and CIMH Mannheim German 675 1,297 550 7–10
Genetic Association Information Network (GAIN) / Bipolar  
Genome Study (BiGS)
European-American 542 649 6.0 7–10
GlaxoSmithKline (GSK) British, Canadian or Scottish 890 902 550 9
Pritzker Neuropsychiatric Disorders Research Consortium European-American 1,130 718 550 9
Systematic Treatment Enhancement Program for Bipolar  
Disorder (STEP1)
European-American 922 645 500K 7,8
Systematic Treatment Enhancement Program for Bipolar  
Disorder (STEP2)
European-American 659 192 5.0 8
Thematically Organized Psychosis (TOP) Study Norwegian 203 349 6.0 11
Trinity College Dublin Irish 150 797 6.0 8
University College London (UCL) British 457 495 500K 7,8
University of Edinburgh Scottish 282 275 6.0 8
Wellcome Trust Case-Control Consortium (WTCCC) British 1,571 2,931 500K 6,8,9
tOtAl 7,481 9,250
aCases include BD1, BD2, SAB, BD-NOS (see supplementary table 1). bMost controls were not screened for psychiatric disease. A subset of 33%, however, were screened, see the supplementary 
Note. cPlatforms are 6.0, Affymetrix Genome-Wide Human SNP Array 6.0; 5.0, Affymetrix Genome-Wide Human SNP Array 5.0; 500K, Affymetrix GeneChip Human Mapping 500K Array; 550,  
Illumina HumanHap 550. dPrimary publication reporting individual sample level genotypes for bipolar disorder are listed. See the supplementary Note for a fuller description of publications and 
supplementary table 1 for the sample origins in the primary GWAS analyses.
table 2 Primary GWAs association results for four most significant regions
SNP Chr. Positiona Nearest gene A1b/A2 A1 frequencyc ORd (95% CI) Praw PGC
rs10994397 10 61,949,130 ANK3d T/C 0.06 1.35 (1.48–1.23) 5.5 × 10−10 7.1 × 10−9
rs9371601 6 152,832,266 SYNE1 T/G 0.36 1.15 (1.21–1.10) 4.3 × 10−9 4.3 × 10−8
rs7296288 12 47,766,235 Many C/A 0.48 1.15 (1.20–1.09) 9.4 × 10−9 8.4 × 10−8
rs12576775 11 78,754,841 ODZ4 G/A 0.18 1.18 (1.25–1.11) 2.7 × 10−8 2.1 × 10−7
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We performed a conditional analysis that included the 34 inde-
pendent SNPs listed in Table 3. We identified SNPs within 1 Mb of 
the most associated SNP that continued to show evidence of associa-
tion (conditional PGC < 10−4) in three regions. A region-specific con-
ditional analysis showed conditional association at 3p21.1 (rs736408, 
conditional PGC = 8.1 × 10−7), 10q21.2 (rs9804190, conditional 
PGC = 7.3 × 10−5) and 15q14 (rs16966413, conditional PGC = 7.3 × 
10−5) (Supplementary Fig. 6). On chromosomes 3 and 15, the SNP 
most strongly associated after conditioning was >500 kb from the 
 conditioning SNP, and multiple genes are present in the intervening 
interval. On chromosome 10, we observed additional less strongly 
associated conditionally independent SNPs located upstream of the 
table 3 Association results for the primary GWAs, replication and combined samples
Primary GWAS Replicationa
Combined GWAS and 
replication
SNP Chr.b Positionc A1 A2 PGC ORd P1-sided OR PGC OR Genes in the LD region
rs4765913 12 2,290,157 A T 6.50 × 10−6 1.15 1.60 × 10−4 1.13 1.52 × 10−8 1.14 CACNA1C
rs10896135 11 66,307,578 C G 8.46 × 10−6 0.88 1.47 × 10−3 0.91 1.56 × 10−7 0.89 ZDHHC24, YIF1A, TMEM151A, SYT12, SPTBN2, 
SLC29A2, SF3B2, RIN1, RCE1, RBM4B, RBM4, 
RBM14, RAB1B, PELI3, PC, PACS1, NPAS4, MRPL11, 
LRFN4, KLC2, GAL3ST3, DPP3, CTSF, CNIH2, 
CD248, CCS, CCDC87, C11orf86, C11orf80, BRMS1, 
BBS1, B3GNT1, ACTN3
rs2070615* 12 47,504,438 A G 4.00 × 10−5 0.90 2.52 × 10−3 0.93 1.02 × 10−6 0.91 RND1, DDX23, CACNB3
rs12576775 11 78,754,841 A G 2.09 × 10−7 0.85 7.59 × 10−3 0.92 4.40 × 10−8 0.88 ODZ4
rs2175420* 11 78,801,531 C T 2.90 × 10−5 0.87 7.80 × 10−3 0.92 2.35 × 10−6 0.89 ODZ4
rs3845817 2 65,612,029 C T 1.65 × 10−5 0.90 8.98 × 10−3 0.94 1.76 × 10−6 0.91
rs2176528 2 194,580,428 C G 3.98 × 10−5 1.15 0.0104 1.09 3.71 × 10−6 1.12
rs4660531 1 41,612,409 G T 3.16 × 10−5 0.89 0.0111 0.93 3.44 × 10−6 0.91
rs7578035 2 98,749,324 G T 1.83 × 10−5 1.12 0.0129 1.06 2.77 × 10−6 1.09 TXNDC9, TSGA10, REV1, MRPL30, MITD1, MGAT4A, 
LYG1, LYG2, LIPT1, EIF5B, C2orf55, C2orf15
rs2287921 19 53,920,084 C T 1.68 × 10−5 1.12 0.0137 1.06 3.08 × 10−6 1.10 SPHK2, SEC1, RPL18, RASIP1, NTN5, MAMSTR, 
IZUMO1, FUT2, FUT1, FGF21, FAM83E, DBP, CA11
rs11168751* 12 47,505,405 C G 1.80 × 10−5 0.84 0.0143 0.90 2.51 × 10−6 0.86 CACNB3
rs7296288 12 47,766,235 A C 8.39 × 10−8 0.87 0.0150 0.94 5.41 × 10−8 0.90 TUBA1B, TUBA1A, RHEBL1, PRKAG1, MLL2, LMBR1L,  
DHH, DDN
rs7827290 8 142,369,497 G T 3.54 × 10−5 1.13 0.0167 1.06 8.75 × 10−6 1.10 LOC731779, GPR20
rs12730292 1 79,027,350 C G 2.37 × 10−5 1.12 0.0171 1.06 5.02 × 10−6 1.10
rs12912251 15 36,773,660 G T 9.57 × 10−6 1.13 0.0204 1.06 3.27 × 10−6 1.10 C15orf53
rs4332037 7 1,917,335 C T 1.78 × 10−5 0.87 0.0300 0.93 7.25 × 10−6 0.90 MAD1L1
rs6550435 3 36,839,493 G T 1.97 × 10−5 1.12 0.0326 1.05 9.32 × 10−6 1.09 LBA1
rs17395886 4 162,498,835 A C 2.18 × 10−5 0.86 0.0351 0.93 1.06 × 10−5 0.89 FSTL5
rs6746896 2 96,774,676 A G 2.33 × 10−6 1.14 0.0386 1.05 2.36 × 10−6 1.10 LMAN2L, FER1L5, CNNM4
rs736408 3 52,810,394 C T 1.22 × 10−6 1.14 0.0465 1.05 2.19 × 10−6 1.10 WDR82, TWF2, TNNC1, TMEM110, TLR9, STAB1, 
SPCS1, SNORD69, SNORD19, SNORD19B, SFMBT1, 
SEMA3G, RFT1, PRKCD, PPM1M, PHF7, PBRM1, 
NT5DC2, NISCH, NEK4, MUSTN1, LOC440957, 
ITIH1, ITIH3, ITIH4, GNL3, GLYCTK, GLT8D1, 
DNAH1, BAP1, ALAS1
rs11162405 1 78,242,248 A G 2.54 × 10−5 0.90 0.0476 0.96 1.82 × 10−5 0.92 ZZZ3, USP33, NEXN, MGC27382, GIPC2, FUBP1, 
FAM73A, DNAJB4, AK5
rs9804190 10 61,509,837 C T 3.06 × 10−5 1.17 0.0963 1.04 1.20 × 10−4 1.10 ANK3
rs9371601 6 152,832,266 G T 4.27 × 10−8 0.87 0.103 0.97 6.71 × 10−7 0.91 SYNE1
rs3774609 3 53,807,943 G T 1.14 × 10−5 0.89 0.107 0.97 3.73 × 10−5 0.92 CHDH, CACNA1D
rs10994397 10 61,949,130 C T 7.08 × 10−9 0.74 0.116 0.94 3.08 × 10−7 0.82 ANK3
rs4668059 2 168,874,528 C T 4.45 × 10−5 1.18 0.158 1.04 1.32 × 10−4 1.12 STK39
rs16966413 15 36,267,191 A G 4.74 × 10−5 0.84 0.160 0.95 9.97 × 10−5 0.88 SPRED1
rs6102917 20 40,652,833 C G 3.88 × 10−5 1.44 0.165 1.11 8.46 × 10−5 1.31 PTPRT
rs11085829 19 13,035,312 A G 4.03 × 10−6 0.87 0.175 0.97 6.96 × 10−5 0.92 NFIX
rs875326 1 173,556,022 C T 2.51 × 10−5 1.15 0.183 1.03 1.11 × 10−4 1.10 TNR
rs13245097* 7 2,307,581 C T 3.81 × 10−5 1.13 0.196 1.02 3.24 × 10−4 1.08 SNX8, NUDT1, MAD1L1, FTSJ2
rs780148 10 80,605,089 C G 4.66 × 10−5 1.12 0.230 1.03 1.40 × 10−4 1.09 ZMIZ1
rs2281587 10 105,367,339 C T 1.96 × 10−5 1.12 0.372 1.01 3.78 × 10−4 1.07 SH3PXD2A, NEURL
rs10776799 1 115,674,570 G T 4.84 × 10−5 1.15 0.434 1.01 1.25 × 10−3 1.08 NGF
rs263906 1 101,750,922 C T 2.42 × 10−5 1.13 0.440 1.01 4.43 × 10−4 1.08
rs10028075 4 87,186,854 C T 8.96 × 10−6 0.89 1.00 1.02 2.04 × 10−3 0.95 MAPK10
rs3968 9 4,931,997 C G 2.09 × 10−5 1.17 1.00 0.92 0.0174 1.04
rs8006348 14 50,595,223 A G 4.91 × 10−5 0.89 1.00 1.05 0.0637 0.95 TRIM9
aSNP bp position on Build 36. bThe odds ratio (OR) is predicted toward allele A1. cReplication case and control sample details can be found in the supplementary Note; 4% of the controls were 
screened for psychiatric disorders.  dOdds ratio. Bold indicates genome-wide statistical significance. PGC, genomic control P value; Chr., chromosome; LD, linkage disequilibrium.  *SNPs not 
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5′ end of ANK3, in an intron of ANK3 and at the 3′ end of the longest 
transcript (705 kb in length). In each of these three regions, the asso-
ciation signals remaining after conditioning could arise from multi-
ple causal variants, from a single rare causal variant in incomplete LD 
with the tested SNPs or could represent false-positive associations.
To provide direct evidence for a polygenic basis for bipolar 
 disorder—as implied by the polygenic component shared between 
bipolar disorder and schizophrenia previously reported19—we 
repeated the analysis performed by the International Schizophrenia 
Consortium using bipolar disorder discovery samples. We observed 
enrichment of putatively associated bipolar disorder ‘score alleles’ 
in target sample cases compared to controls for all discovery P value 
thresholds (Supplementary Table 9).
A parallel study was performed by PGC schizophrenia inves-
tigators. We tested whether a combined analysis of PGC bipolar 
disorder and PGC schizophrenia data (eliminating known over-
lapping control samples) would show stronger association for the 
five most strongly associated SNPs supplemented by the additional 
genome-wide significant replication region in CACNA1C. In the 
combined bipolar disorder and schizophrenia analysis, two SNPs 
showed stronger association compared to the bipolar disorder 
GWAS alone: rs4765913 in CACNA1C (combined Praw = 7.7 × 10−8 
compared to bipolar disorder Praw = 1.35 × 10−6) and rs736408 in a 
multigene region containing NEK4-ITIH1-ITIH3-ITIH4 (combined 
Praw = 8.4 × 10−9 compared to bipolar disorder Praw = 2.00 × 10−7) 
(Supplementary Table 10).
In summary, we observed primary association signals that reached 
genome-wide significance in the regions of ANK3 and SYNE1 and two 
signals near genome-wide significance on chromosome 12 and in the 
region of ODZ4. Although in our independent replication sample we 
did not find additional support for ANK3 or SYNE1, this is consist-
ent with overestimation of the original ORs and should not be taken 
to disprove association. Data from additional samples are needed to 
resolve this.
The most notable finding is the abundance of replication signals. 
The number of nominal associations in the same direction of effect is 
highly unlikely to be a chance observation and strongly implies that 
many of the signals will ultimately turn out to be true associations. 
Such results are expected under a highly polygenic model, where 
there are few or no variants of large effect. As is typical in studies of 
 complex genetic disorders, our findings explain only a small fraction 
of bipolar disorder heritability. Our data are consistent with many 
common susceptibility variants of relatively weak effect19 potentially 
operating together with rarer variants20. 
Although this was the largest GWAS study 
of bipolar disorder to date, our sample size 
remains modest compared to other recent 
studies and is therefore likely underpowered. 
Subject ascertainment, assessment and popu-
lation variation could also potentially reduce 
power to detect loci with relatively specific 
phenotypic effects.
A pathway analysis showed significant 
enrichment of CACNA1C and CACNA1D, 
which encode the major L-type α subunits 
found in the brain, consistent with a prior 
literature regarding the role of ion channels 
in bipolar disorder, the mood stabilizing 
effects of ion channel modulating drugs and 
the specific treatment literature suggesting 
direct efficacy of L-type calcium channel 
blockers in the treatment of bipolar disorder21. The CACNA1C SNP 
rs1006737 has been associated with several alterations in structural22 
and functional magnetic resonance imaging23–25. Several groups have 
previously implicated CACNA1C in other adult psychiatric disor-
ders, in particular, schizophrenia and major depression26–29. L-type 
 calcium channels regulate changes in gene regulation responsible for 
many aspects of neuronal plasticity and may have direct effects on 
 transcription29. Taken together, this should lead to renewed biological 
investigation of calcium channels in psychiatric disease. ODZ4, 
located on chromosome 11, encodes a member of a family of cell 
surface proteins, the teneurins, and is related to the Drosophila pair-
rule gene ten-m (odz). These genes are likely involved in cell surface 
signaling and neuronal pathfinding.
Three of our top five regions harbor non-coding RNAs. miR-708, 
a member of a conserved mammalian microRNA family, is located 
in the first intron of ODZ4. Three small nucleolar RNAs (snoRNAs), 
SNORD69, SNORD19 and SNORD19B, are located on chromosome 
3p21.1 and belong to the C/D family of snoRNAs. Finally, a 121-base 
non-coding RNA with homology to 5S-ribosomal RNA is within the 
SYNE1 association region. The role of microRNAs and non-coding 
RNAs in neurodevelopmental disorders is increasingly apparent in 
Rett’s syndrome, fragile X syndrome and schizophrenia. Our study 
represents, to our knowledge, the first connection of these regions to 
bipolar disorder.
In conclusion, we obtained strong evidence for replication of mul-
tiple signals in bipolar disorder. In particular, we support prior find-
ings in CACNA1C and now identify an intronic variant in ODZ4 as 
being associated with bipolar disorder. These replication results imply 
that data from additional samples, both from GWAS and sequenc-
ing, will identify more of the genetic architecture of bipolar disorder. 
Finally, our combined analysis with schizophrenia illuminates the 
growing appreciation of the shared genetic epidemiology of these two 
disorders30 and the shared polygenic contribution to risk19.
URLs. Genetic Cluster Computer, http://www.geneticcluster.org/; 
NCBI gene2go, ftp.ncbi.nlm.nih.gov/gene/DATA/gene2go.gz; 
INRICH, http://atgu.mgh.harvard.edu/inrich.
MethOdS
Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
Figure 1 Results are shown as –log10 P for genotyped and imputed SNPs. The most associated 
SNP in the primary analysis is shown as a small purple triangle. The most associated SNP in the 
combined analysis is shown as a large purple triangle. The colors of the remaining markers reflects 
r2 values with the most associated SNP. The recombination rate from CEU HapMap data (second  
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Sample description. These analyses used bipolar disorder case-control GWAS 
data from international collections (‘primary studies’). Sample ascertainment 
details are provided in prior publications (Table 1) and the Supplementary 
Note. Standardized semi-structured interviews were used to collect clinical 
information about lifetime history of psychiatric illness, and operational crite-
ria were applied to make lifetime diagnoses. All cases have experienced patho-
logically relevant episodes of elevated mood (mania or hypomania) and meet 
the criteria for bipolar disorder within the primary study classification system. 
Controls were selected from the same geographical and ethnic populations as 
the cases and had a low probability of having bipolar disorder. Some control 
selection criteria excluded individuals with a personal history of mood dis-
order, and other controls were unscreened. The distribution of diagnoses is 
shown in Supplementary Table 1. Protocols and assessment procedures were 
approved by the institutional review boards of the authors’ institutions. All 
 participants provided written informed consent, and consent allowed the 
 samples to be used within the current analyses.
PGC central data quality control pipeline. Primary study genotype data were 
deposited on the Genetic Cluster Computer (see URLs) hosted by the Dutch 
National Computing and Networking Services. Data were generated using 
four different genotyping platforms (Affymetrix 500K, 5.0, 6.0 and Illumina 
HumanHap 500). Data were processed by the PGC central analysis commit-
tee pipeline, which performed semi-automated formatting, quality testing, 
inter- and intra-study relatedness checks and imputation. First, SNP names, 
positions and strand were harmonized. For SNPs with <5% missing data, indi-
viduals were retained if the missing genotype rate per individual was <0.02. 
Subsequently, SNPs were retained if the missing genotype rate per SNP was 
<0.02, the missing genotype rate between cases and controls per SNP was <0.02 
(absolute difference), Hardy-Weinberg equilibrium (controls) P > 1 × 10−6 and 
the frequency difference to the HapMap reference was <0.15. This removed 
380,959 SNPs and 177 individuals from the 11 bipolar disorder studies. After 
these steps, there were 10,926 controls and 8,338 cases for analysis.
Data were imputed using BEAGLE 3.0 (ref. 16), with phased HapMap 
phase 2 data as a reference. Each dataset was imputed separately, splitting 
into imputation batches of 300 individuals randomly, keeping the case-control 
ratio balanced.
Duplicate sample elimination. Using PLINK17, we found that 3,714 individuals 
in 2,316 pairs were duplicated, which we defined as a pair of samples with an 
estimated probability of genome-wide identity-by-descent of sharing two chro-
mosomes above 90%. To remove duplicates, in order to preserve case:control 
ratios as close to 50:50 as possible and to favor data generated using more recent 
platforms, we preferentially kept samples from duplicate pairs in the order as 
follows: BOMA-bipolar study, TOP, STEP2, NIMH/PRITZKER, GAIN/BiGS, 
STEP1, TRINITY COLLEGE, UEDINBURGH, GSK, UCL and then WTCCC. 
The final dataset contained only unique individuals, with each individual 
belonging to exactly one sample. We further detected instances of previously 
unknown close relatedness. After removing a small number of parent-offspring, 
full-sibling and half-sibling pairs, we were left with N = 16,731 individuals in 
16,254 families (including 477 known sibling pairs from NIMH/PRITZKER).
Ancestry evaluation. We used the WTCCC control sample to select SNPs 
in approximate linkage equilibrium to calculate multi-dimensional scaling 
(MDS) components to assess and correct for population stratification. This 
yielded N = 21,134 autosomal SNPs, genotyped on all platforms, which is 
sufficient for this MDS analysis. We calculated the top 20 MDS components. 
Based on inspection of between- and within-sample correlation with the phe-
notype, we retained the top five components, which were used as covariates 
along with ten binary dummy variables to control for differences between the 
11 samples (Supplementary Fig. 1).
Association analyses. Primary analyses. Following initial quality control and 
elimination of duplicates, there were 16,731 individuals and 2,541,952 SNPs. 
Analyses are based on the 2,415,422 SNPs with minor allele frequency >1% and 
imputation r2 > 0.3 with a HapMap SNP. The primary analysis was a logistic 
regression of disease state on single-SNP allele dosage including covariates to 
account for site as well as the first five quantitative indices of ancestry based 
on the MDS analyses. To adjust for the relatedness between the siblings, we 
used a robust Huber-White sandwich variance estimator for cluster-correlated 
observations. All association analyses were performed using PLINK v1.07 
(ref. 17) with no clinical covariates. The genomic inflation factor (λ) was calcu-
lated as the ratio between the observed and expected median χ2 statistics, was 
1.148 and was used to correct for the degree of inflation (Supplementary Fig. 2). 
The LD-based associated regions with P < 5 × 10−5 presented in Supplementary 
Table 2 were based on the clumping approach (PLINK). Specifically, we took all 
SNPs significant at P < 5 × 10−5 that had not already been clumped (denoting 
these as index SNPs) and formed clumps of all other SNPs that are within 1 Mb of 
the index SNP, in LD with the index SNP (r2 > 0.2) or nominally associated with 
disease (P < 0.05). This approach grouped SNPs in LD space rather than physical 
distance. This clumping approach resulted in 38 SNPs with P < 5 × 10−5.
Replication analyses. From each replication sample, we obtained informa-
tion on P values, ORs, standard errors (SE), minor allele frequencies and the 
associated risk allele for SNPs listed in Supplementary Table 2. If the target SNP 
listed in Supplementary Table 2 was not present in the replication dataset, we 
obtained a proxy SNP in strong LD and weighted the SE to account for the lack 
of information: SEW = SE/sqrt(r2). The estimate (ES), β, is the natural logarithm 
of the odds ratio. We performed a standard meta-analysis to estimate a common 
















We combined the odds ratios and standard errors from the discovery and 
replication samples using a fixed effect meta-analysis. The final P values are 
genomic-control adjusted based on a λ of 1.176, estimated from all available 
GWAS data (from both wave 1 and the replication samples).
Gene Ontology (GO) enrichment analyses. We looked for terms enriched 
for genes in the most associated intervals. We started with the 38 intervals 
described above. Only 34 regions were analyzed by collapsing any regions that 
(i) physically overlapped, (ii) spanned the same gene or (iii) did not show con-
ditionally independent association signals. Three regions contain SNPs that 
had low pairwise r2 but did not show independent association when covarying 
for the neighboring SNP, reflecting high LD measured in terms of D′ and not 
indicative of truly independent signals. The enrichment analysis depended on 
the assumption of independence between intervals so as not to double count 
genes. The final list contained 34 independent regions.
We used NCBI gene2go (see URLs) and mapped Entrez GeneIDs to gene 
symbols and hg18 coordinates using the UCSC Genome Browser. Of the 9,834 
total GO terms, we restricted the analysis to terms with at least 2 and not more 
than 200 human genes, leaving 6,482 GO terms (‘targets’). For each target, we 
counted the number of association intervals that contained at least one target 
gene; we required that at least two intervals contained at least one gene from 
each target. We evaluated the probability of observing the number of intersect-
ing intervals by chance alone using a permutation procedure (implemented 
in INRICH software (see URLs)). Specifically, we randomly placed each inde-
pendent interval in an alternate position on the genome matching for the total 
number of SNPs and implied new size of the interval (the distance in bp was 
within a factor of 0.8–1.2 of the original) and the total number of genes. In this 
manner, we controlled for potential biases caused by SNP and gene density 
and gene size. We repeated the permutation 100,000 times and corrected for 
multiple testing by evaluating the distribution of minimum empirical P values 
under the null hypothesis given 6,482 tested targets. The corrected empirical 
P values implicitly account for the non-independence of the GO terms.
Conditional analyses. To identify additional signals after accounting for 
the effects of the initial GWAS signals, we performed a conditional analysis 
including the most strongly associated SNPs in the analysis of each SNP. In 
regions in which we detected a potential secondary signal(s) (PGC < 10−4), we 





























SNP or the potential secondary signal SNP(s). The P values are genomic-
control corrected (Supplementary Fig. 6).
Polygene analyses. We used the PGC bipolar dataset for the independent 
replication and the polygenic analysis by the International Schizophrenia 
Consortium (ISC)19. Briefly, we partitioned the PGC sample into a target 
(the German sample) and a discovery set (all other samples). We used only 
genotyped SNPs common to all platforms and which were in in linkage equi-
librium, yielding ~20,000 SNPs. We estimated the odds ratios from the ten 
sites, excluding the German sample, by a fixed-effect meta-analysis and took 
the log of these odds ratios as weights to calculate the scores in the target 
sample. Following the ISC methods, we selected discovery sample P-value 
thresholds of P < 0.01, P < 0.05, P < 0.1, P < 0.2, P < 0.3, P < 0.4 and P < 0.5. 
For each threshold, we performed a logistic regression of disease state in the 
target sample on the polygenic score from the remaining independent samples 
covarying for the rate of genotyping failure and MDS components to adjust 
for potential confounders. We observed significant enrichment of putatively 
associated ‘score alleles’ in the target sample cases compared to the controls 
(P values and pseudo r2 values presented; all effects were in the expected 
direction, with a higher score in the cases compared to the controls).
Analysis of top bipolar disorder findings in schizophrenia. We investigated 
the top five bipolar disorder signals (nominal uncorrected Praw < 5 × 10−7) from 
our primary bipolar dataset compared to a similar set of data prepared from the 
PGC schizophrenia group31. Following our analysis in the replication dataset, a 
sixth signal representing the calcium channel region was added. Because there 
was substantial overlap in the controls between the two studies, a strategy was 
employed to randomly assign each control to either the bipolar disorder or the 
schizophrenia dataset. Briefly, for the 14,044 controls samples in both datasets, a 
PLINK pi-hat > 0.9 was used to identify identical controls. Only one individual 
was retained for analysis and was randomly assigned to either the bipolar dis-
order or the schizophrenia set. The primary analysis was a logistic regression 
of disease state on single SNP allele dosage similar to those described above 
for our primary GWAS sample association. We included covariates to account 
for site as well as the quantitative indices (the first five plus three additional 
indices that showed some correlation with phenotype) of ancestry based on 
multi-dimensional scaling.
31.  The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. 
Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 






























Corrigendum: Large-scale genome-wide association analysis of bipolar  
disorder identifies a new susceptibility locus near ODZ4
Psychiatric GWAS Consortium Bipolar Disorder Working Group 
Nat. Genet. 43, 977–983 (2011); published online 18 September 2011; corrected after print 21 June 2012
In the version of this article initially published, there were errors in the consortium membership list and the associated affiliations and in the 
acknowledgements and contributions sections. These errors and their corrections are detailed below by section. 
Consortium members:
Janice M. Fullerton was omitted from the membership list and has now been added with affiliations 76 and 77. Phil H. Lee was listed incorrectly as 
Phil L. Hyoun. Fan Meng was listed incorrectly as Fan Guo Meng, and the associated affiliation has been changed from 51 to 54. Robert Thompson 
was assigned affiliation 50; the correct affiliation is 54. Marian Hamshere and Valentina Moskvina were assigned affiliation 26; the correct affili-
ation for both is 22. Richard Day was assigned affiliation 47; the correct affiliation is 46. Jun Li was assigned affiliation 24; the correct affiliation 
is 48. In addition to the affiliation originally listed for Sebastian Zöllner and Peng Zhang, both have now also been assigned affiliation 4. Howard 
Endenberg has now also been assigned affiliation 12, and Shaun Purcell has now also been assigned affiliation 1.
Consortium affiliations:
Affiliation 46 was originally given as the University of Dundee School of Medicine, Nethergate, Dundee, UK. The correct affiliation is the Division 
of Neuroscience, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK. Affiliation 47 was originally given as the School of 
Neurology, Neurobiology and Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, UK. The correct affiliation is the Department of Human 
Genetics, University of Michigan, Ann Arbor, Michigan, USA. This affiliation was also listed out of order and has now been changed to affiliation 
48. Affiliation 76 was originally given as the Prince of Wales Medical Institute, Sydney, Australia. The correct affiliation is Neuroscience Research 
Australia, Sydney, Australia.
Acknowledgments: 
The Stanley Foundation for Medical Research was listed as a source of funding. The correct name is the Stanley Medical Research Institute, and 
the Merck Genome Research Institute has also been added as a source of support. 
Contributions: 
In four instances, the contribution of Sven Cichon was indicated with the incorrect spelling S. Chichon instead of S. Cichon. Manuel A. Ferreira 
(M.A.F.) was incorrectly listed as a contributor to manuscript preparation. Manuel A. Ferreira (M.A.F.) was listed as a contributor to primary 
study data at the NIMH/Pritzke; the correct contributor was Matthew Flickinger (M.F.). In the section listing contributors to replication data, 
Neuroscience Research Australia was named incorrectly as the Prince of Wales Medical Institute, and Janice M. Fullerton (J.M.F.) has been added 
as a contributor at this site and at the University of New South Wales.
The errors detailed above have been corrected in the HTML and PDF versions of the article. In addition, the subsections of the contributions sec-
tion detailing the individuals contributing to primary study data and replication data were omitted from the original HTML version of the article, 
and this error has now been corrected.np
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